Treatment Options (1)

Dr. Jason R. Williams of The Williams Cancer Institute was recently featured on the podcast “Targeted Talks”, along with medical oncologist Dr. George R. Simon, of the University of Texas MD Anderson Cancer Center. The two discussed the importance community oncologists have on the future of treatment of non-small cell lung cancer.

According to Dr. Williams, “every treatment option for non-small cell lung cancer now involves individualized immunotherapy.” Though oncologists had been resistant to including it in the plan of care for their patients, most have adapted as studies have revealed success, and more drugs are FDA approved.

Patients are asked as soon as they receive pathology reports whether they would like to start immunotherapy. There are limitations to success, as more data continues to be gathered on the subject. One promising option is the addition of cryoablation immunotherapy.

immune system

Intratumoral immunotherapy is one of the most recent scientific advances for cancer treatments. This discovery has had some amazing results, including eliminating traces of cancer cells within the patient’s body.

This treatment is centered around the idea of using the tumor as the vaccine to fight against cancer. It entails directly injecting high concentrations of immunostimulatory products, coupled with a small amount of medication, into the tumor.

One study published in the journal The Oncologist has shown that the overall response rate of this treatment was 55 percent, in a treatment course done over 12 weeks. Those who underwent a second course had a 26% to 51% success rate.

Here are five benefits to intratumoral immunotherapy:

CATEGORIES

ARCHIVES